ASGCT’s Q1 2026 landscape report points to continued growth in cell, gene, and RNA therapy development, including a 30% increase in startup funding versus Q1 2025. ASGCT CEO David Barrett said the field has 42 approved gene therapies worldwide and 38 approved RNA therapies, alongside 76 non-genetically modified cell therapies.